BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 7553646)

  • 41. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
    Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
    Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: results of the German Neuroblastoma Study Group.
    Christiansen H; Delattre O; Fuchs S; Theobald M; Christiansen NM; Berthold F; Lampert F
    Prog Clin Biol Res; 1994; 385():19-25. PubMed ID: 7972212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Sensibility and specificity of N-myc oncogene with respect to other prognostic factors in 15 neuroblastomas].
    Queizán A; García-Miguel P; Belló MJ; Castresana JC; Rey JA; Pestaña A
    Cir Pediatr; 1995 Jul; 8(3):96-8. PubMed ID: 8527322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
    Iolascon A; Lo Cunsolo C; Giordani L; Cusano R; Mazzocco K; Boumgartner M; Ghisellini P; Faienza MF; Boni L; De Bernardi B; Conte M; Romeo G; Tonini GP
    Cancer Lett; 1998 Aug; 130(1-2):83-92. PubMed ID: 9751260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.
    Mora J; Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Fazzari M; Heller G; Chen L; Gerald WL
    J Mol Diagn; 2000 Feb; 2(1):37-46. PubMed ID: 11272900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
    Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig.
    Bauer A; Savelyeva L; Claas A; Praml C; Berthold F; Schwab M
    Genes Chromosomes Cancer; 2001 Jul; 31(3):228-39. PubMed ID: 11391793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss.
    Hoshi M; Otagiri N; Shiwaku HO; Asakawa S; Shimizu N; Kaneko Y; Ohi R; Hayashi Y; Horii A
    Br J Cancer; 2000 Jun; 82(11):1801-7. PubMed ID: 10839294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma.
    Suzuki T; Yokota J; Mugishima H; Okabe I; Ookuni M; Sugimura T; Terada M
    Cancer Res; 1989 Mar; 49(5):1095-8. PubMed ID: 2563671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of heterozygosity for chromosome 1p in familial neuroblastoma.
    Tonini GP; Lo Cunsolo C; Cusano R; Iolascon A; Dagnino M; Conte M; Milanaccio C; De Bernardi B; Mazzocco K; Scaruffi P
    Eur J Cancer; 1997 Oct; 33(12):1953-6. PubMed ID: 9516831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of genetic rearrangements in human neuroblastomas.
    Brodeur GM
    Clin Chem; 1989 Jul; 35(7 Suppl):B38-42. PubMed ID: 2568197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
    Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
    Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tumor cytogenetics and prognosis in neuroblastoma].
    Christiansen H; Lampert F
    Monatsschr Kinderheilkd; 1989 Oct; 137(10):666-71. PubMed ID: 2586532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.